Antidepressants, antipsychotics, anxiolytics: from chemistry and pharmacology to clinical application: in 2 v. (Weinheim, 2006). - ОГЛАВЛЕНИЕ / CONTENTS
Навигация

 
Выставка новых поступлений  |  Поступления иностранных книг в библиотеки СО РАН : 2003 | 2006 |2008
ОбложкаAntidepressants, antipsychotics, anxiolytics: from chemistry and pharmacology to clinical application: in 2 v. / ed. by Buschmann H. et al. - Weinheim: Wiley-VCH, 2007. - 1214 p. - ISBN 978-3-527-31058-6
 

Оглавление / Contents
 
Preface 1 .................................................... XIII
Preface 2 ...................................................... XV
A view from Esteve ............................................ XIX
Dedication and Acknowledgements ............................... XXI
List of Contributors ........................................ XXIII
Glossary ..................................................... XXIX

VOLUME 1

1. Depressive Disorders ......................................... 1

   1.1. Introductory and Basic Aspects .......................... 3
        Neurobiology of Mood Disorders .......................... 3
           Luz Romero, Ana Montero, Begoña Fernández and
           José M. Vela
        1.1.1. Definition of mood disorders, impact on a
               global scale and unmet needs ..................... 3
        1.1.2. Causes and associations in mood disorders:
               genetics and pharmaco-genetics .................. 10
        1.1.3. Pathogenesis of mood disorders .................. 14
        1.1.4. Concluding remarks .............................. 33
   References .................................................. 35

   1.2. Clinics ................................................ 51
        Clinical Aspects of Depressive Disorders 
           Rosario Peérez-Egea, Victor Pérez,
           Dolors Puigdemont and Enric Alvarez
        1.2.1. Introduction .................................... 51
        1.2.2. Classification .................................. 52
        1.2.3. Epidemiology .................................... 61
        1.2.4. Physiopathology ................................. 63
        1.2.5. Treatment of affective disorders ................ 68
   References ................................................. 104

   1.3. Pharmacology .......................................... 111
        Pharmacotherapy of Depression
           Begoña Fernández, Luz Romero and
           Ana Montero
        1.3.1. Introduction ................................... 111
        1.3.2. Current antidepressant treatments .............. 112
        1.3.3. New strategies for antidepressant treatments ... 116
        1.3.4. Concluding remarks ............................. 131
   References ................................................. 132

   1.4. Experimental Research ................................. 141
        Modeling Human Depression by Animal Models
           Ana Montero, Begoña Fernández and
           Luz Romero
        1.4.1. Introduction ................................... 141
        1.4.2. Types of validity .............................. 142
        1.4.3. Animal models of depression .................... 145
        1.4.4. Some concluding remarks ........................ 160
   References ................................................. 162
   
   1.5. Chemistry ............................................. 173
        Marketed Drugs and Drugs in Development
           Jörg Holenz, Josê Luis Díaz and Helmut Buschmann
        1.5.1. Summary of drug classes ........................ 173
        1.5.2. Tricyclic and tetracyclic antidepressants ...... 173
        1.5.3. Serotonergic agents ............................ 193
        1.5.4. Noradrenaline reuptake inhibitors .............. 231
        1.5.5. Monoamine oxidase inhibitors ................... 233
        1.5.6. Miscellaneous agents ........................... 239
        1.5.7. Compounds launched in single countries ......... 248
        1.5.8. New opportunities for marketed drugs ........... 249
        1.5.9. Summary of antidepressants in development ...... 249
   References ................................................. 261

2. Schizophrenia and Other Psychoses .......................... 297

   2.1. Introductory and Basic Aspects ........................ 299
        Current Status and Challenges in Schizophrenia
        Research
           Francesc Artigas
        2.1.1. Introduction ................................... 299
        2.1.2. Clinical diagnosis and assessment of
               schizophrenia .................................. 300
        2.1.3. Epidemiology ................................... 306
        2.1.4. Course of schizophrenia ........................ 307
        2.1.5. Brain pathology in schizophrenia ............... 308
        2.1.6. Pathogenesis and pathophysiology of
               schizophrenia .................................. 316
        2.1.7. Concluding remarks ............................. 326
   References	327

   2.2. Clinics ............................................... 335
        Schizophrenia: A Clinical Review
           Salvador Ros and Francisco Javier Arranz
        2.2.1. Introduction ................................... 335
        2.2.2. Background ..................................... 336
        2.2.3. Epidemiology ................................... 341
        2.2.4. General semiology .............................. 341
        2.2.5. Positive symptoms in schizophrenia ............. 342
        2.2.6. Negative symptoms in schizophrenia.............. 345
        2.2.7. Cognitive alterations in schizophrenia ......... 347
        2.2.8. Characteristics of cognitive deterioration
               in schizophrenia ............................... 350
        2.2.9. Methods to evaluate cognitive deterioration
               in schizophrenia ............................... 356
        2.2.10.Affective symptoms in schizophrenia ............ 358
        2.2.11.Schizophrenia and suicide ...................... 360
        2.2.12.Onset and states ............................... 365
        2.2.13.Etiopathogeny .................................. 367
        2.2.14.Prognosis ...................................... 373
        2.2.15.Schizophrenia therapy .......................... 375
   References ................................................. 378

   2.3. Pharmacology .......................................... 389
        Pharmacotherapy of Schizophrenia
           Analía Bortolozzi, Llorenc Díaz-Mataix and
           Francesc Artigas
        2.3.1. Antipsychotic drugs: introduction .............. 389
        2.3.2. Atypical Antipsychotics: introduction .......... 401
        2.3.3. Other major investigational approaches ......... 425
        2.3.4. Concluding remarks: challenges in drug
               discovery ...................................... 429
   References	432

   2.4. Experimental Research ................................. 449
        Modeling schizophrenia in experimental animals
           Pau Celada, Anna Castañé, Albert Adell and
           Francesc Artigas
        2.4.1. Introduction ................................... 449
        2.4.2. Neurophysiology of schizophrenia ............... 450
        2.4.3. Pharmacological models of schizophrenia ........ 453
        2.4.4. Neurodevelopmental models ...................... 464
        2.4.5. Genetic models ................................. 468
        2.4.6. Other animal models ............................ 473
        2.4.7. Concluding remarks ............................. 474
   References ................................................. 475

   2.5. Chemistry ............................................. 491
        Marketed Drugs and Drugs in Development
           Antonio Párraga, Jörg Holenz and Helmut Buschmann
        2.5.1. Summary of drug classes ........................ 491
        2.5.2. Typical antipsychotics ......................... 494
        2.5.3. Atypical antipsychotics ........................ 549
        2.5.4. Drugs in development ........................... 579
   References ................................................. 586

VOLUME 2

3. Anxiety .................................................... 617

   3.1. Introductory and Basic Aspects
        3.1.1. Definition and classification of anxiety
               disorders ...................................... 619
           Francisca López-Ríos, Serafin Gómez-Martin
           and Antonio Molina-Moreno
        References ............................................ 643
        3.1.2. Epidemiology of anxiety disorders .............. 645
           Flor Zaldívar-Basurto and José M. Garcia-Montes
        References ............................................ 662
        3.1.3. Etiology of Anxiety ............................ 667
           Margarita Moreno, Ginesa López-Crespo and
           Pilar Flores
        References ............................................ 678
        3.1.4. Anxiety disorders and drug abuse ............... 685
           Diana Cardona-Mena, Margarita Moreno and
           Pilar Flores
        References ............................................ 701
        3.1.5. Neurobiology of anxiety (I): Panic disorder,
               posttraumatic stress disorder, social phobia
               and obsessive-compulsive disorder .............. 709
           Lola Roldán-Tapia, Ginesa López-Crespo, Francisco
           Antonio Nieto-Escámez and Diana Cardona-Mena
        References ............................................ 743
        3.1.6. Neurobiology of anxiety (II): Childhood
               anxiety, generalized anxiety disorder and
               mixed anxiety-depressive disorder .............. 761
           Francisco Antonio Nieto-Escámez, Ginesa
           López-Crespo, Lola Roldán-Tapia and
           Fernando Cañadas-Pérez
        References............................................. 785
        3.1.7. Consequences of anxiety on memory
               processes (I): Introductory and clinical
               aspects ........................................ 803
           Fernando Cañadas-Pérez, Francisco Antonio Nieto-
           Escámez, Lola Roldán-Tapia and Ginesa
           Löpez-Crespo
        References ............................................ 821
        3.1.8. Consequences of anxiety on memory
               processes (II): Neurobiologicai aspects ........ 831
           Francisco Nieto-Escámez, Fernando Cañadas-Pérez,
           Lola Roldán-Tapia and Fernando Sánchez-Santed
        References ............................................ 864

   3.2. Clinics ............................................... 881
        Clinical Aspects of Anxiety
           Blanca Gutiérrez and Jorge Cervilla
        3.2.1. Conceptual introduction ........................ 881
        3.2.2. Panic disorder ................................. 882
        3.2.3. Generalized anxiety disorder ................... 885
        3.2.4. Phobic anxiety disorders ....................... 888
        3.2.5. Obsessive-compulsive disorder .................. 890
        3.2.6. Conclusion ..................................... 892
   References ................................................. 893

   3.3. Pharmacology .......................................... 895
        Pharmacology of Anxiety
           José Manuel Baeyens
        3.3.1. Introduction ................................... 895
        3.3.2. Drugs used in treatment of anxiety disorders:
               an overview .................................... 896
        3.3.3. Generalized anxiety disorder (GAD) ............. 902
        3.3.4. Social anxiety disorder (SAD) or social
               phobia ......................................... 905
        3.3.5. Simple or specific phobia ...................... 908
        3.3.6. Panic disorder (PD) ............................ 908
        3.3.7. Posttraumatic stress disorder (PTSD) ........... 911
        3.3.8. Obsessive-compulsive disorder (OCD) ............ 914
   References ................................................. 918
   
   3.4. Experimental Research ................................. 923
        Modeling Human Anxiety by Animal Models
           Enrique Portillo and José Miguel Vela
        3.4.1. General concepts on animal models .............. 923
        3.4.2. General aspects of human anxiety ............... 925
        3.4.3. Animal anxiety ................................. 926
        3.4.4. Potential issues in animal models of anxiety ... 937
        3.4.5. Conclusions: Implication for drug discovery .... 940
   References ................................................. 942

   3.5. Chemistry ............................................. 951
        Marketed Drugs and Drugs in Development
           Mónica García-López, Susana Yenes, Helmut
           Buschmann and Antoni Torrens
        3.5.1. Summary of drug classes ........................ 951
        3.5.2. Benzodiazepines ................................ 951
        3.5.3. Serotonergic drugs ............................. 999
        3.5.4. GABAergic agents .............................. 1006
        3.5.5. Dopaminergic agents ........................... 1011
        3.5.6. Serotonin reuptake stimulants ................. 1017
        3.5.7. 5-HT2 receptor antagonists .................... 1019
        3.5.8. β-adrenoceptor antagonists .................... 1021
        3.5.9. Glucocorticoid receptor antagonists ........... 1026
        3.5.10.GAT-1 inhibitors .............................. 1029
        3.5.11.Calcium channel blockers ...................... 1032
        3.5.12.No-described mechanism of action .............. 1039
        3.5.13.Drugs in development .......................... 1051
   References ................................................ 1069

4. Attention Deficit and Hyperactivity Disorders ............. 1089

   4.1. Introductory and Basic Aspects ....................... 1091
        Neurobiological aspects of Attention Deficit and
        Hyperactivity Disorders
           Javier Burgueño, Rafael Franco and
           Francisco Ciruela
        4.1.1. Definition and introductory clues ............. 1091
        4.1.2. Etiology of ADHD .............................. 1095
   References ................................................ 1100

   4.2. Clinics .............................................. 1105
        Attention Deficit Hyperactivity Disorder:
        Clinical and Therapeutic Facts
           Francisco Javier Arranz and Salvador Ros
        4.2.1. Introduction .................................. 1105
        4.2.2. Epidemiology .................................. 1108
        4.2.3. Etiology ...................................... 1114
        4.2.4. Pathophysiology ............................... 1118
        4.2.5. Clinical features ............................. 1122
   References ................................................ 1146

   4.3. Pharmacology ......................................... 1155
        Pharmacology: Targets of Drug Action
           Francisco Ciruela, Rafael Franco and
           Javier Burgueño
        4.3.1. Neurobiological evidence for ADHD as an
               organic phenomenon ............................ 1155
        4.3.2. Neurochemistry of ADHD: Neurotransmitter
               imbalance ..................................... 1156
   References ................................................ 1177

   4.4. Chemistry ............................................ 1183
        Marketed Drugs and Drugs in Development
           Jörg Holenz, Jose Luis Díaz and Helmut Buschmann
        4.4.1. Summary of drug classes ....................... 1183
        4.4.2. Drugs in development .......................... 1192
   References ................................................ 1194

Index ........................................................ 1197


 
Выставка новых поступлений  |  Поступления иностранных книг в библиотеки СО РАН : 2003 | 2006 |2008
 

[О библиотеке | Академгородок | Новости | Выставки | Ресурсы | Библиография | Партнеры | ИнфоЛоция | Поиск]
  Пожелания и письма: branch@gpntbsib.ru
© 1997-2024 Отделение ГПНТБ СО РАН (Новосибирск)
Статистика доступов: архив | текущая статистика
 

Документ изменен: Wed Feb 27 14:52:32 2019. Размер: 19,841 bytes.
Посещение N 1570 c 26.04.2010